Alvogen nabs four Pfizer products; Brazil's pharma market to approach $48B by 2020: report;

> Alvogen has acquired a portfolio of four pharma products from Pfizer ($PFE). Release

> Brazil's pharma market will near $48 billion by 2020, GlobalData says. Release

> Amneal has created a new biosciences unit that will focus on injectables, oncologics, biosimilars and other products that have high barriers to entry. Release

> Mylan ($MYL) has launched a generic of Pfizer's anti-infective combo Zosyn. Release

> British health secretary Jeremy Hunt is to create tough new rules designed to criminalize some gifts and financial payments between doctors and pharma companies. Report

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.